The Spanish Association of Biosimilar Medicines - BioSim and the Spanish Society of Health Directors - SEDISA have signed a collaboration agreement that establishes, among other actions, the carrying out of various training, information, dissemination actions, as well as studies on biosimilar medicines, and which represents the beginning of a stable collaboration framework between both organizations.
The agreement has been signed by Joaquín Rodrigo, president of BioSim, and by Joaquín Estévez, president of SEDISA, and specifies various ways of joint work to promote the opportunities that biosimilar medicines offer to improve healthcare and its levels of efficiency . Specifically, objectives framed in three areas are established: training, dissemination and generation of new knowledge, as well as the permanent coordination and communication mechanisms that make them operational.
Common goals for sustainable healthcare
According to the signed text, BioSim and SEDISA will share scientific and technical means aimed at improving the levels of information of health managers in relation to biosimilar medicines. Thus, BioSim will offer its scientific knowledge, means and channels of dissemination and communication to carry out the necessary work for the execution of joint programs and activities, and SEDISA will collaborate with BioSim in the public presentation of the material and in the actions that result from the joint work provided for in the collaboration agreement.
On the other hand, the research and analysis works that BioSim prepares and that include relevant knowledge for health management will be transferred to SEDISA for possible dissemination, which will enjoy full rights of exploitation, reproduction, public communication and distribution in all types of formats. and without territorial limitation. At the same time, SEDISA will put at the service of BioSim the scientific and technical means at its disposal to achieve the objectives set out in the agreement, and will collaborate with BioSim in the public presentation of the material or actions that result from the joint work.
For Joaquín Rodrigo, "BioSim represents the companies that work in the pharmaceutical area that can do the most to improve the efficiency of health organizations, biosimilar medicines, and for this reason it was necessary to establish a line of permanent collaboration with the association that represents managers of these organizations. We are very satisfied for having established this framework of joint work, because our interest in making Spanish healthcare more efficient and sustainable is also shared. Hence, we can generate this common space with SEDISA, which will surely result in an improvement in the role of biosimilars in favor of more efficient results-oriented healthcare, something that we share with the healthcare managers of our country”.
For Joaquín Estévez, “the health manager has the responsibility of knowing all the possibilities to offer patients as the best option, from the medical point of view and also from the perspective of the efficiency of the system as a whole. Therefore, for SEDISA, it is essential to establish collaboration agreements that provide information, training and valuable content to facilitate professionalized health management, based on quality and results”.
Both signatories have highlighted that "biosimilars can improve access to biological therapies for high-impact pathologies, as well as provide efficiency that will help the health system to alleviate its economic burdens and improve the joint value of its activity."
“BioSim and SEDISA are aware that our health is increasingly valued according to the health value that it is capable of contributing, something that it is required to do efficiently and equitably. This is where biosimilar medicines are called to make an increasingly relevant contribution in terms of sustainability and impact on health”.
About biosimilar medicines and BioSim
www.biosim.es | @biosim_es
A biosimilar is a biological medicine that is equivalent in quality, efficacy and safety to an original biological medicine, called a reference product. The dosage and route of administration must be the same, and the biosimilar is authorized for all or some of the indications approved for the reference biologic. Biosimilars allow a greater number of patients to access biological treatments due to the reduction in their cost. Currently, the European Union has authorized the marketing of fifty of these drugs, and it is expected that in the coming years a growing number of products and approved indications will be available.
BioSim, the Spanish Association of Biosimilars, is a non-profit organization whose purpose is to foster and promote scientific, business and technical interests common to the Spanish biosimilar medicines industry, for which it welcomes and represents all pharmaceutical companies established in Spain that research, develop, produce and/or market biosimilar medicines, being able to form part of it both laboratories that are already operating in the biosimilars market and original product companies that have launched, or are going to launch march, a division of biosimilars; be it for research, development, production or marketing.
About SEDISA
www.sedisa.net | @SEDISA_NET
The Spanish Society of Health Directors (SEDISA) is a private, non-profit association, with its own legal personality and independent from that of its members. It is made up of more than 1.600 professionals who work in the health sector and who occupy a managerial role in their companies, with a profile in which initiative and the ability to generate recognition predominate.
The main objective of the Company since its creation is to professionalize health management, carrying out projects and activities that contribute to the promotion, development, protection and defense of health services in general and particularly the study and improvement of managerial and directive functions. of health, as well as the representation, management and defense of the professional interests of its members. The ultimate goal is to work for quality health management, based on health results, efficiency and sustainability.
